Nyxoah (NYXH) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Company background and leadership

• CEO has six years of leadership, with prior experience at Eli Lilly, Medtronic, and Nevro.

• Company founded in 2009 by Robert Taub, focusing on patient-centered alternatives for obstructive sleep apnea.

• Achieved CE Mark in Europe in 2019, followed by reimbursement in Germany.

• Transitioned to a public company with two IPOs, raising $200 million, last on Nasdaq in July 2021.

Market overview and treatment landscape

• Obstructive sleep apnea (OSA) leads to significant health risks, including increased stroke and cardiovascular risk.

• CPAP masks are the current standard but have low long-term compliance, with up to 50% discontinuation after two years.

• U.S. market has about 500,000 patients eligible for hypoglossal nerve stimulation, but only 30,000 currently treated.

• Entry of a second company is expected to increase awareness and options for both physicians and patients.

Clinical development and trial results

• DREAM pivotal study designed to match endpoints and patient phenotypes of the Inspire STAR trial.

• DREAM included a broader AHI range (15-65) and required patients to sleep at least 60 minutes on their back.

• Results showed comparable efficacy to STAR, with airway maintained regardless of sleep position.

• Full DREAM data to be presented at AAO-HNS Congress, with publication targeted for JAMA.